Interestingly, we found a consistent upregulation of Galectin-1 mRNA levels in a set of paired melanoma samples obtained from the same patients before BRAF-targeted therapy and upon the onset of drug resistance (Figure 1A and Figure S1B); importantly, NRP1 expression also increased in most resistant tumors (Figure S1B), which was consistent with previous findings [7]. This evidence concerns the gene LGALS1 and melanoma.